-1.05% $967.98
America/New_York / 16 mai 2024 @ 16:00
Live Signal Regeneron Pharmaceuticals Inc
Buy @ $972.52
Issued: 16 mai 2024 @ 12:58 / Return: -0.47%
Previous Signal: sell @ 15 mai 2024 @ 13:00 - Return: -0.71 %
$1 invested is now $1.15 or 14.84 % *
(* In 14 weeks 3 days 46 minutes and 16 seconds .)
Dividend: X | Profitable: Y | Good Trading Volume: Y
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Last live signals for Regeneron Pharmaceuticals
The Live signals presented on this page help you to determine when to buy or sell Regeneron Pharmaceuticals. The signals has upwards to 1 minute delay and like all signals there is an given chance for error or mistakes. The signals are not definite and stockinvestor.us hold no responsibility for any action taken upon these signals as clearly described in the TOS. The signals is based on technical analysis based on a wide range of indicators.
Right now there is a buy signal in the stock from the rsi14 signal,and we believe current price holds an opportunity to make profit.
Answer last updated: 16 mai 2024 @ 16:00
We cannot find any recorded dividends paid in our systems.
No, the consensus target for Regeneron Pharmaceuticals Inc is $867.60, which is $0, or -10.37 % below today's price. The analysts has low target of $604.00 and a high target of $1 185.00
We cannot find data for Regeneron Pharmaceuticals 10 years ago, but if you had invested on Friday 17th of May 2019 when price was $304.94 you would have made a profit of $663.04 per share or 217.43 %
Yes, the average daily trading liquidity for Regeneron Pharmaceuticals is $457 316 . You should therefore be able to get in and out of your positions relatively fast.
Regeneron Pharmaceuticals has little of the business financed by loans. This put the company at lower risk in periods of high inflation where cost of borrowing money usually go up. With a high cash flow to debt ratio of 2.39 the company's ability to pay of the debt is good. Regeneron Pharmaceuticals has a very good net profit margin of 29.45% and should have very high tolerances against inflation as the profit margin can be reduced to maintain market positions and overall sales.
We have calculated the inflation risk for Regeneron Pharmaceuticals to be [0 of 1]
US inflation for March 2024 was 0.38%. Over last 12 months the US inflation is 3.48%. The 10 year treasury yield that indicate the future interest level is currently 4.36 and is up 0.47 over last 30 days.